CIRM Funded Clinical Trials

A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia


Disease Area:
Beta Thalassemia
Investigator:
CIRM Grant:
CLIN2-11031 (Closed)
Award Value:
$5,150,000.00
Trial Sponsor:
Sangamo BioSciences, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Completed
Targeted Enrollment:
5
ClinicalTrials.gov ID:

Details:

Sangamo, Inc. is testing genetically engineered blood stem cells for the treatment of beta-thalassemia, a severe form of anemia caused by mutations in the hemoglobin gene. This genetic disorder requires life-long blood transfusions and carries a life expectancy of only 30-50 years. The Sangamo therapy takes a patient’s own blood stem cells and, using a gene-editing technology called zinc finger nuclease (ZFN), provides a functional copy of the hemoglobin gene. These modified cells are given back to the patient which potentially will eliminate the need for chronic transfusions and its associated complications.

Design:

Open label, single arm study

Goal:

Safety and tolerability. Efficacy, change from baseline HbF levels, frequency and volume of RBC transfusions.

News about this clinical trial:

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov